|

Empagliflozin (oral) Clinical Trials

1 actively recruiting trial

Pipeline

Phase 4: 1

Top Sponsors

  • Erbil Polytechnic University1

Indications

  • Obese Patients (BMI ≥ 30 kg/m²)1
  • Obese Diabetics1
  • Diabetes1
  • Type 2 Diabetes1

Other1 trial

The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity
Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.